Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Partnership to Promote Multiple-Use Filters and Connectors for the Biopharmaceutical Industry

By BiotechDaily International staff writers
Posted on 30 Sep 2013
Image: The Intact Modular Filler (IMF) is a fully integrated, automatic filling machine performing all filling activities, including container loading, positioning, filling, and container unloading. The IMF can fill glass or plastic containers of various shapes and sizes (bottles, vials, pouches) with high precision and consistency (Photo courtesy of Medical Instill Technologies).
Image: The Intact Modular Filler (IMF) is a fully integrated, automatic filling machine performing all filling activities, including container loading, positioning, filling, and container unloading. The IMF can fill glass or plastic containers of various shapes and sizes (bottles, vials, pouches) with high precision and consistency (Photo courtesy of Medical Instill Technologies).
A partnership has been established to promote the utilization of multiple-use sterile filtration and connection devices in the biopharmaceutical industry.

ATMI, Inc. (Danbury, CT, USA), a global technology company and leader in single-use bioprocess solutions, announced that it will be investing in the INTACT family of sterile connector and sterile fill technologies developed by Medical Instill Technologies (New Milford, CT, USA), a company dedicated to developing solutions for the transfer and packaging of high purity fluids. Medinstill says that INTACT connector is the only multiple-use sterile connector now available that guarantees no contact between the liquid path and the external environment ensuring no ingress of air, bacteria, yeasts, or molds.

The Intact Modular Filler (IMF) is a fully integrated, automatic filling machine performing all filling activities, including container loading, positioning, filling, and container unloading. The IMF can fill glass or plastic containers of various shapes and sizes (bottles, vials, pouches) with high precision and consistency.

ATMI and Medinstill will market and manufacture INTACT technology solutions for the biopharmaceutical industry. This technology is scalable from small lots in benchtop systems to industrial-sized units for manufacturers in the global biopharmaceutical and vaccine markets.

“ATMI has a strong history of internal innovation as well as collaboration with other innovators,” said, Doug Neugold CEO of ATMI. “Collaboration with Medinstill is another great example of this strategy. Through this investment, we will develop a suite of products that address critical issues from our customers’ perspective as they continue to adopt single-use technology and other new inventions. Our customers are looking for ways to reduce cost, minimize time to market and increase manufacturing flexibility. The INTACT solutions that we are developing with Medinstill enable efficiencies that will help us help them realize their objectives.”

“We are happy to partner with a company of ATMI’s stature,” said Dr. Daniel Py, chairman of Medinstill. “With its global reach and history of technical innovation in biopharmaceutical manufacturing, I believe ATMI can be instrumental in allowing us to bring products with the highest safety levels to those in need. The INTACT technology provides a means to rapidly reduce drug shortages while overcoming the difficulties associated with installing and running aseptic lines in emerging markets, such as access to specially trained personnel, all at a fraction of the cost of traditional aseptic filling lines. The synergy between our INTACT Closed Transfer Systems and disposable technologies from ATMI allows us together to quickly install turnkey fill finish lines, bringing many benefits to a large number of manufacturers. We look forward to a long and successful relationship with ATMI.”

Related Links:
ATMI, Inc.
Medical Instill Technologies



Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Lab Technologies

view channel
Image: The VIAFLO Assist pipette adapter (Photo courtesy of INTEGRA Biosciences).

Pipetting Assistant Helps Prevent Repetitive Strain Injuries

A powerful pipetting accessory makes life easier for technicians in both clinical and research laboratories. Prolonged and repetitive pipetting sessions bear the risk of strain and fatigue, often resulting... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.